- Aytu reported Q4 results in October that beat estimates across the board with revenue of $14.86 million, surpassing the $11.24 million revenue analysts were projecting.
- A careful review of the data supports an estimate of profitability in the upcoming Q1 and an expected increase in share price based on applying industry average benchmarks.
- Aytu continues to explore exciting business opportunities including additional product acquisitions and development of their groundbreaking Healight technology, which is in FDA-approved human trials.
For further details see:
Aytu BioScience: The Barcode King Is Poised For An Epic Breakout